Notice of Proposed Sale · 144
Cencora, Inc.
CORNYSEEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Cencora, Inc.
- Issuer CIK
- 0001140859
- SEC file number
- 001-16671
- Phone
- 610-727-7000
- Person for whose account securities are to be sold
- Cleary James F
- Relationships to issuer
- Officer
- Street
- 1 WEST FIRST AVENUE
- City
- CONSHOHOCKEN
- State / country code
- PA
- Postal code
- 19428
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 20,000 | 6,333,096.30 | 190,827,165 | 08/06/2026 | NYSE | Fidelity Brokerage Services LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Fidelity Brokerage Services LLC
- Street
- 900 Salem Street
- City
- Smithfield
- State / country code
- RI
- Postal code
- 02917
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 11/08/2025 | Restricted Stock Vesting | Issuer | 1,734 | N | 11/08/2025 | Compensation |
| Common | 11/09/2025 | Restricted Stock Vesting | Issuer | 1,701 | N | 11/09/2025 | Compensation |
| Common | 11/20/2025 | Restricted Stock Vesting | Issuer | 1,052 | N | 11/20/2025 | Compensation |
| Common | 12/17/2025 | Stock Option Exercise | Issuer | 8,299 | N | 12/17/2025 | Cash |
| Common | 03/11/2026 | Restricted Stock Vesting | Issuer | 7,214 | N | 03/11/2026 | Compensation |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/06/2026
- Signed
- /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for James Cleary Jr.
Company context
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #16 on the Global Fortune 500 with more than $300 billion in annual revenue. Learn more at investor.cencora.com.
Current securities
Recent company filings
- Regulation FD DisclosureNov 4, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureNov 4, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureOct 21, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 25, 2026
- 144 filingSep 16, 2026